Stock Price

The tech firm's new funding addresses urgent debt amid Nasdaq delisting threats, revealing a complex financial maneuver to keep its K-culture dreams alive.

Facing a mountain of debt, Sable Offshore Corp. is raising capital to refinance and restart controversial oil operations, sending its stock plunging.

Flash Sports & Media aims to vertically integrate with a creative, no-cash deal. But does the ambitious strategy align with its precarious financial reality?

As QXO finalizes its TopBuild acquisition, an overwhelming shareholder preference for cash triggers proration, reshaping investor portfolios and an entire industry.

Plus Therapeutics rebrands to Cerenome, signaling a major pivot to an integrated platform combining diagnostics, radiotherapeutics, and AI for CNS cancers.

Sheldon Inwentash's exit from One Bullion's board post-IPO is a classic junior miner move. What does it signal for the company's Botswana gold strategy?

Facing a disconnect between its growing operations and its market price, Sucro Limited is reviewing its strategy. What does this move reveal about the future of sugar?

GRAIL's revolutionary cancer test failed a key trial, wiping out billions and sparking a fraud lawsuit. A deep dive into the fallout for investors and science.

An investigation into nursing home giant Ensign reveals a troubling intersection of high finance, regulatory loopholes, and the vulnerable lives in its care.

Barry Diller wants to buy MGM Resorts, a company where he's a director. Now, a legal probe is asking if the deal serves all shareholders or just one.

A securities fraud lawsuit against Peabody Energy alleges a classic tale of corporate overpromise, exposing the risks of opaque disclosures in a volatile market.

Struggling apparel firm 707 Cayman Holdings appoints a Web3 pioneer to lead a pivot into AI and blockchain. Is it a visionary leap or a desperate gamble?

White River Bancshares' minor correction to its dividend date reveals a major truth: in the world of finance, precision is not just a detail, it's the product.

Live Oak Bank's hire of a top accounting chief isn't just a personnel move. It signals a new age of accountability for digital banks, where growth meets governance.

Just months after a celebrated IPO, digital wealth manager Wealthfront faces a securities fraud probe. A steep drop in deposits and stock price raises tough questions.

FibroBiologics secures $3M with a path to $9M, fueling its promising cell therapy pipeline. But is this a strategic masterstroke or a necessary risk?

Triller Group is dead; long live Eight Holdings. A deep dive into the audacious plan to shed its past, shut down its app, and build a diversified revenue engine.

Hub Group's multi-year accounting scandal reveals deep-seated control failures, sparking a class action lawsuit and wiping out nearly a billion in market value.

An investor rights law firm is investigating the $929M sale of Theravance Biopharma, asking if shareholders are getting a fair deal or if the board failed them.

InTest Corp's inclusion in the Russell 2000/3000 is more than a ticker change. It's a validation of a growth strategy in critical tech sectors.